ClinicalTrials.gg
CompletedNCT00472290Updated Dec 29, 2017Results posted

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

An interventional study of Romiplostim (formerly AMG 531) in Hematology, MDS and Myelodysplastic Syndromes, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-29.

Sponsored by Amgen · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Myelodysplastic Syndromes by Amgen — none open to participants now, none under way, none of them phase 3. Myelodysplastic Syndromes · Amgen.

Enrollment
5th of 11
72 · median 72
Started
2007
the only one that year
No phase
Only one
of the 11
Registered
5th of 11
by date

Among the 11 studies in Myelodysplastic Syndromes by Amgen, this one is the 5th largest by enrollment, is the only one that started in 2007, is the only one with no phase, and was the 5th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 11 studies in Myelodysplastic Syndromes by Amgen is open now. The open studies under Myelodysplastic Syndromes, anywhere →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Myelodysplastic Syndromes by Amgen as a file.
02

Study summary

This is an open label extension study of romiplostim for treatment of thrombocytopenia (platelet count ≤ 50 x 10\^9/L) in MDS subjects. The study is designed to assess the long-term safety of treatment with romiplostim, as measured by incidence of overall adverse events, the incidence of bleeding events, the utilization of platelet transfusions, and the duration of platelet response. The study will further describe the time to disease progression to acute myeloid leukemia (AML) and survival.

03

Conditions studied

  • Hematology
  • MDS
  • Myelodysplastic Syndromes
  • Thrombocytopenia

Keywords

  • Hematology
  • MDS
  • Myelodysplastic Syndromes
  • Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed a romiplostim study for the treatment of thrombocytopenia in subjects with MDS
  • Subject has an Eastern Cooperative Oncology () performance status of 0 to 2
  • Subject had a count ≤ 50 x 10\^9/L since the final dose of product in the parent study
  • Subject or his/her legally acceptable representative provided written before any study-specific procedures were initiated

Exclusion criteria

Exclusion Criteria

  • Subject has been diagnosed with AML or has a blast count ≥ 10% by peripheral blood or bone marrow
  • Subject has a prior history of leukemia
  • Subject has a prior history of bone marrow or stem cell transplantation
  • Subject has a prior (other than in situ cervical cancer, controlled prostate cancer, or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ≥ 3 years before randomization
  • Subject has active or uncontrolled infections
  • Subject has unstable angina, congestive heart failure [ (NYHA) > class II], uncontrolled hypertension (diastolic > 100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction
  • Subject has a history of arterial thrombosis (eg, stroke or ) in the past year
  • Subject has a history of venous thrombosis that currently requires anti-coagulation therapy
  • Subject received interleukin (IL)-11 within 4 weeks of screening
  • Subject previously received a thrombopoietic growth factor (other than romiplostim)
  • Subject has a known to any recombinant E coli-derived product (eg, Infergen®, Neupogen®, Somatropin, Actimmune)
  • Subject is currently enrolled in device or drug study(ies), has not yet completed at least 4 weeks since ending investigational device or drug study(ies) (other than parent romiplostim study), or subject is receiving other investigational agent(s)/device(s)
  • Subject is of and is evidently pregnant (eg, positive human chorionic gonadotropin [HCG] test) or is breast feeding
  • Subject is not using adequate precautions
  • Subject has any kind of disorder that compromises his/her ability to give written (and does not have a legally acceptable representative) or is unable to comply with study procedures
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Open Label Romiplostim (formerly AMG 531)

    Drug: Romiplostim (formerly AMG 531)

Interventions

  • Subjects will begin the study at an initial dose of 750 µg. Except for: * Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response. * Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count.

06

What researchers measure

Primary outcomes

  1. Overall Summary of Adverse Events

    Time frame: During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks .

  2. Incidence of Antibody (AB) Formation

    Time frame: During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks.

Secondary outcomes

  1. Weekly Bleeding Events Per 100 Subject Years

    During the time since the first dose of IP to the end of the treatment period. A single bleeding event was defined as each individual bleeding episode that originated from a specific organ system (eg, gastrointestinal system or central nervous system). A bleeding event that continued for more than 7 days was counted as separate events every eighth day.

    Time frame: During the treatment period. The average duration of romiplostim exposure is 56 weeks.

  2. Platelet Transfusion Events Per 100 Subject Years

    During the time since the first dose of IP to the end of the treatment period. A discrete platelet transfusion event was defined as any number of platelet transfusions administered within a 3-day period. Platelet transfusions administered more than 3 days apart were counted as separate platelet transfusion events.

    Time frame: During the treatment period. The average duration of romiplostim exposure is 56 weeks.

  3. Weeks With Platelet Response Per Year

    During the time since the first dose of IP to the end of the treatment period. Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.

    Time frame: During the treatment period. The average duration of romiplostim exposure is 56 weeks.

  4. Time to First Platelet Response

    Time since first dose of IP to the first platelet response. Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.

    Time frame: During treatment period. The average duration of romiplostim exposure is 56 weeks.

  5. Duration of Platelet Response

    Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.

    Time frame: During treatment period. The average duration of romiplostim exposure is 56 weeks.

07

Results

Posted Jul 15, 2013
Limitations and caveats
Early termination leading to small number of subjects analyzed;

Participant flow

This study was available to subjects who completed a previous romiplostim study for the treatment of thrombocytopenia in subjects with low or intermediate-1 risk MDS. First Subject Enrolled: 17-Jul-2007; Last Subject Enrolled: 15-Feb-2011

Participant flow — Overall Study
MilestoneRomiplostim
Started72
Completed0
Not completed72
Withdrew: Progression of therapy-related mds1
Withdrew: Protocol specified criteria7
Withdrew: Administrative decision37
Withdrew: Death3
Withdrew: Lost to follow-up1
Withdrew: Lack of efficacy1
Withdrew: Disease progression4
Withdrew: Withdrawal by subject5
Withdrew: Adverse event6
Withdrew: Requirement for alternative therapy7

Outcome measures

PrimaryOverall Summary of Adverse Events
Time frame:
During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks .
Reported as:
Number · Participant
Overall Summary of Adverse Events
ParticipantRomiplostim
Subjects Reporting Any AE71
Subjects Reporting Any Treatment-related AE19
Subjects Reporting Any Treat-related Serious AE4
Subjects Reporting Any Serious AE29
Subjects Withdrew Study or Stop IP Due to AE8
SecondaryWeekly Bleeding Events Per 100 Subject Years

During the time since the first dose of IP to the end of the treatment period. A single bleeding event was defined as each individual bleeding episode that originated from a specific organ system (eg, gastrointestinal system or central nervous system). A bleeding event that continued for more than 7 days was counted as separate events every eighth day.

Time frame:
During the treatment period. The average duration of romiplostim exposure is 56 weeks.
Reported as:
Mean · Events/100 subject-year
Weekly Bleeding Events Per 100 Subject Years
Events/100 subject-yearRomiplostim
Weekly Bleeding Events Per 100 Subject Years1120.5 (1047.1 to 1197.7)
SecondaryPlatelet Transfusion Events Per 100 Subject Years

During the time since the first dose of IP to the end of the treatment period. A discrete platelet transfusion event was defined as any number of platelet transfusions administered within a 3-day period. Platelet transfusions administered more than 3 days apart were counted as separate platelet transfusion events.

Time frame:
During the treatment period. The average duration of romiplostim exposure is 56 weeks.
Reported as:
Mean · Events/100 subject-year
Platelet Transfusion Events Per 100 Subject Years
Events/100 subject-yearRomiplostim
Platelet Transfusion Events Per 100 Subject Years204.4 (173.8 to 238.9)
SecondaryWeeks With Platelet Response Per Year

During the time since the first dose of IP to the end of the treatment period. Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.

Time frame:
During the treatment period. The average duration of romiplostim exposure is 56 weeks.
Reported as:
Mean · Weeks/Subject-year
Weeks With Platelet Response Per Year
Weeks/Subject-yearRomiplostim
Weeks With Platelet Response Per Year34.6 (33.3 to 35.9)
SecondaryTime to First Platelet Response

Time since first dose of IP to the first platelet response. Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.

Time frame:
During treatment period. The average duration of romiplostim exposure is 56 weeks.
Reported as:
Median · Weeks
Time to First Platelet Response
WeeksRomiplostim
Time to First Platelet Response2.3 (2.1 to 3.1)
SecondaryDuration of Platelet Response

Platelet response was based on the modified IWG 2006 criteria (Cheson et al, 2006) and was defined as, in the absence of platelet transfusion: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a subject starting with a platelet count of ≥ 20 x 10\^9/L; or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a subject that started with a platelet count \< 20 x 10\^9/L.

Time frame:
During treatment period. The average duration of romiplostim exposure is 56 weeks.
Reported as:
Median · Weeks
Duration of Platelet Response
WeeksRomiplostim
Duration of Platelet Response20.0 ± 49.5
PrimaryIncidence of Antibody (AB) Formation
Time frame:
During treatment period from first dose of IP to End of Study visit, on Average 56 Weeks.
Reported as:
Number · Participant
Incidence of Antibody (AB) Formation
ParticipantRomiplostim
Positive binding AB to IP at or before baseline5 ± 94.7
Neutralizing AB to IP at or before baseline0
Binding AB positive to IP post-baseline only5
Persistent binding AB positive to IP4
Transient binding AB positive to IP1
Positive binding AB to TPO at or before baseline4
Neutralizing AB to TPO at or before baseline0
Binding AB positive to TPO post-baseline only3
Persistent binding AB positive to TPO2
Transient binding AB positive to TPO1

Adverse events

Collected over The average duration is 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romiplostim—29/72 (40.3%)66/72 (91.7%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventRomiplostim
PneumoniaInfections and infestations3/72
HaematomaVascular disorders3/72
AnaemiaBlood and lymphatic system disorders2/72
Febrile neutropeniaBlood and lymphatic system disorders2/72
BronchitisInfections and infestations2/72
Urinary tract infectionInfections and infestations2/72
ArthralgiaMusculoskeletal and connective tissue disorders2/72
AnxietyPsychiatric disorders2/72
HaematuriaRenal and urinary disorders2/72
Renal failure acuteRenal and urinary disorders2/72
Most frequent other events
Showing 10 of 49
Most frequent other events
EventRomiplostim
EpistaxisRespiratory, thoracic and mediastinal disorders23/72
CoughRespiratory, thoracic and mediastinal disorders17/72
FatigueGeneral disorders15/72
ArthralgiaMusculoskeletal and connective tissue disorders14/72
AnaemiaBlood and lymphatic system disorders13/72
Abdominal painGastrointestinal disorders12/72
ContusionInjury, poisoning and procedural complications12/72
ConstipationGastrointestinal disorders11/72
HeadacheNervous system disorders11/72
HaematomaVascular disorders11/72

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Romiplostim
Mean68.9 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Romiplostim
Female32
Male40
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participant)Romiplostim
White or Caucasian61
Black or African American4
Hispanic or Latino3
Other4
Myelodysplastic Syndromes World Health Organization Classification at Study Screening
Myelodysplastic Syndromes World Health Organization Classification at Study Screening(Participants)Romiplostim
RA: Refractory Anemia20
RARS: Refractory Anemia with Ringed Sideroblasts1
RAEB-1: Refractory Anemia with Excess Blasts-17
RAEB-2: Refractory Anemia with Excess Blasts-22
RCMD:Refractory cytopenia w multilineage dysplasia24
RCMD-RS: RCMD and ringed sideroblasts3
MDS-U: Myelodysplastic syndrome - unclassified15
MDS associated with isolated del(5q)0
Eastern Cooperative Oncology (ECOG) performance status
Eastern Cooperative Oncology (ECOG) performance status(Participants)Romiplostim
0: Fully active42
1: Can carry out light or sedentary work25
2: Capable of selfcare but unable to work5
>=3: Capable of only limited selfcare or worse0
Baseline Platelet Count
Baseline Platelet Count(10^9/L)Romiplostim
Mean27.6 ± 15.5
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017 Sep;178(6):906-913. doi: 10.1111/bjh.14792. Epub 2017 Jun 14. PubMed 28616874 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2007 to primary completion in Jul 2011, 51 months.

Results were first posted in Jul 2013, 1 year 11 months after primary completion.

Of 58 interventional studies with no phase under Myelodysplastic Syndromes, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 125. This study's 51 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2007
First posted
May 11, 2007
StartActual
Apr 1, 2007
Primary completionActual
Jul 18, 2011
CompletionActual
Dec 26, 2011
Results first posted
Jul 15, 2013
Last update
Dec 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00472290
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 11, 2007
Start date
Apr 1, 2007
Primary completion
Jul 18, 2011
Completion
Dec 26, 2011
Results posted
Jul 15, 2013
Last update
Dec 29, 2017

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion